201516 30042015 David Hwang Consultant Oncologist Wendy Cook Research Delivery Manager Head and Neck Tumour Group National Perspective Data from Portfolio ODP Cut off 210815 Head and Neck Tumour Group National Perspective ID: 799810
Download The PPT/PDF document "Head & Neck SSG Research –" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Head & Neck SSG Research – 2015/16
30/04/2015
David Hwang Consultant Oncologist
Wendy Cook Research Delivery Manager
Slide2Head and Neck Tumour Group National Perspective
Data from Portfolio ODP – Cut off 21/08/15
Slide3Head and Neck Tumour Group National Perspective
Data from Portfolio ODP – Cut off 21/08/15
Network
2014/2015
2015/2016
Commercial
Non-Commercial
Total
Rank
Commercial
Non-Commercial
Total
Rank
East Midlands
0
86
86
11
0
5
5
10
Eastern
0
74
74
12
0
4
4
11
Greater Manchester
3
201
204
6
0
22
22
5
Kent, Surrey and Sussex
0
142
142
9
0
4
4
11
North East and North Cumbria
0
131
131
10
0
9
9
9
North Thames
5
209
214
5
1
16
17
7
North West Coast
1
191
192
7
0
4
4
11
North West London
0
59
59
13
0
21
21
6
South London
32
221
253
3
2
37
39
2
South West Peninsula
1
57
58
14
0
0
0
14
Thames Valley and South Midlands
0
24
24
15
0
0
0
14
Wessex
6
299
305
1
0
58
58
1
West Midlands
0
165
165
8
1
10
11
8
West of England
0
243
243
4
0
25
25
4
Yorkshire and Humber
0
279
279
2
0
33
33
3
Slide4Slide5Head and Neck Tumour Group Open StudiesSouth West Peninsula
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
7
De-ESCALaTE
HPV
11723
Non-Commercial
Interventional
Yes
2
HOPON
4550
Non-Commercial
Interventional
Yes
6
IoN
10876
Non-Commercial
Interventional
Yes
13
NCRN206 - LUX-adjuvant
Afatinib
after
chemoradiation
in primary
unresectable
HNC
11522
Commercial
Interventional
No
1
SEND
2069
Non-Commercial
Interventional
Yes
1
Slide6Head & Neck Tumour Group Open StudiesEast Midlands
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
De-ESCALaTE
HPV
11723
Non-Commercial
Interventional
Yes
7
IoN
10876
Non-Commercial
Interventional
Yes
12
NCRN206 - LUX-adjuvant
Afatinib
after
chemoradiation
in primary
unresectable
HNC
11522
Commercial
Interventional
No
4
SEND
2069
Non-Commercial
Interventional
Yes
8
Slide7Head and Neck Tumour Group Open StudiesEastern
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
10
IoN
10876
Non-Commercial
Interventional
Yes
16
NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)
16203
Non-Commercial
Interventional
No
1
SEND
2069
Non-Commercial
Interventional
Yes
2
Slide8Head and Neck Tumour Group Open StudiesGreater Manchester
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
Head and Neck Cancer: molecular, cellular and immunological mechanisms
8130
Non-Commercial
Observational
No
28
HOPON
4550
Non-Commercial
Interventional
Yes
4
IoN
10876
Non-Commercial
Interventional
Yes
17
NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141
16460
Commercial
Interventional
No
2
NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC
11522
Commercial
Interventional
No
1
NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo
14907
Commercial
Interventional
No
1
NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)
16203
Non-Commercial
Interventional
No
17
SEND
2069
Non-Commercial
Interventional
Yes
21
Slide9Head and Neck Tumour Group Open StudiesKent, Surrey and Sussex
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
12
De-ESCALaTE HPV
11723
Non-Commercial
Interventional
Yes
10
HOPON
4550
Non-Commercial
Interventional
Yes
1
IoN
10876
Non-Commercial
Interventional
Yes
18
SEND
2069
Non-Commercial
Interventional
Yes
64
Slide10Head and Neck Tumour Group Open StudiesNorth East and North Cumbria
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
9
De-ESCALaTE HPV
11723
Non-Commercial
Interventional
Yes
6
IoN
10876
Non-Commercial
Interventional
Yes
48
Resources for Living (R4L) Pilot
16705
Non-Commercial
Both
No
17
SEND
2069
Non-Commercial
Interventional
Yes
7
THRIFT
15036
Non-Commercial
Observational
No
2
Slide11Head and Neck Tumour Group Open StudiesNorth Thames
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
17
ElaTION
17373
Non-Commercial
Both
Yes (LC)
6
Genetic factors involved in eyelid mBCC and SGC
14687
Non-Commercial
Observational
Yes (LC)
54
IoN
10876
Non-Commercial
Interventional
Yes
12
NCRN362 - Safety of PC-A11 with laser light application in recurrent head & neck SCC
11926
Commercial
Interventional
No
6
NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo
14907
Commercial
Interventional
No
2
PATRIOT
17568
Non-Commercial
Interventional
No
6
SEND
2069
Non-Commercial
Interventional
Yes
130
SIP SMART: Swallowing Intervention package - Self Monitoring, Assessment & Rehabilitation Training
17043
Non-Commercial
Both
No
13
Slide12Head and Neck Tumour Group Open StudiesNorth West Coast
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
3
DAHANCA 21
13565
Non-Commercial
Interventional
Yes
3
De-ESCALaTE HPV
11723
Non-Commercial
Interventional
Yes
3
HOPON
4550
Non-Commercial
Interventional
Yes
67
NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141
16460
Commercial
Interventional
No
1
NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)
16203
Non-Commercial
Interventional
No
3
SEND
2069
Non-Commercial
Interventional
Yes
15
Slide13Head and Neck Tumour Group Open StudiesNorth West London
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
2
ElaTION
17373
Non-Commercial
Both
Yes (LC)
21
IoN
10876
Non-Commercial
Interventional
Yes
5
Slide14Head and Neck Tumour Group Open StudiesSouth London
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
40
BoHEMIaN
Study
13125
Non-Commercial
Interventional
No
20
COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial
13400
Non-Commercial
Interventional
No
32
De-ESCALaTE
HPV
11723
Non-Commercial
Interventional
Yes
7
ElaTION
17373
Non-Commercial
Both
Yes (LC)
5
Genetic factors involved in eyelid
mBCC
and SGC
14687
Non-Commercial
Observational
Yes (LC)
37
HOPON
4550
Non-Commercial
Interventional
Yes
1
INSIGHT
13860
Non-Commercial
Interventional
No
36
IoN
10876
Non-Commercial
Interventional
Yes
23
NCRN - 2376 Caprelsa in MTC
15014
Commercial
Observational
No
2
NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141
16460
Commercial
Interventional
No
21
NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC
11522
Commercial
Interventional
No
25
NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo
14907
Commercial
Interventional
No
1
NIMRAD (
NIMorazole
/placebo plus
RADiotherapy
in head and neck cancer)
16203
Non-Commercial
Interventional
No
3
PATRIOT
17568
Non-Commercial
Interventional
No
7
SEND
2069
Non-Commercial
Interventional
Yes
5
T4 immunotherapy of head and neck cancer
19183
Non-Commercial
Interventional
No
1
Slide15Head and Neck Tumour Group Open Studies
Thames Valley and South Midlands
Data from Portfolio ODP – Cut off 21/08/15
No open studies on Portfolio ODP
Slide16Head and Neck Tumour Group Open Studies
Wessex
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
10
COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial
13400
Non-Commercial
Interventional
No
31
ElaTION
17373
Non-Commercial
Both
Yes (LC)
6
Head and Neck Cancer: molecular, cellular and immunological mechanisms
8130
Non-Commercial
Observational
No
700
HOPON
4550
Non-Commercial
Interventional
Yes
3
IoN
10876
Non-Commercial
Interventional
Yes
7
NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141
16460
Commercial
Interventional
No
6
SEND
2069
Non-Commercial
Interventional
Yes
28
Slide17Head & Neck Tumour Group Open StudiesWest Midlands
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
30
CANC - 3672 - Phase II MEDI4736 in SCCHN
19009
Commercial
Interventional
No
1
COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial
13400
Non-Commercial
Interventional
No
11
De-ESCALaTE HPV
11723
Non-Commercial
Interventional
Yes
39
HOPON
4550
Non-Commercial
Interventional
Yes
11
IoN
10876
Non-Commercial
Interventional
Yes
2
NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)
16203
Non-Commercial
Interventional
No
9
SEND
2069
Non-Commercial
Interventional
Yes
23
Slide18Head & Neck Tumour Group Open StudiesWest of England
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
24
De-ESCALaTE HPV
11723
Non-Commercial
Interventional
Yes
34
Developing a core information set for consent to oral cancer surgery
15348
Non-Commercial
Observational
Yes (LC)
117
HOPON
4550
Non-Commercial
Interventional
Yes
3
IoN
10876
Non-Commercial
Interventional
Yes
20
NIMRAD (
NIMorazole
/placebo plus
RADiotherapy
in head and neck cancer)
16203
Non-Commercial
Interventional
No
2
Slide19Head & Neck Tumour Group Open StudiesYorkshire and Humber
Data from Portfolio ODP – Cut off 21/08/15
Study Name
UKCRN ID
Study Type
Study Design
Open to New Sites?
Total Recruitment
ART DECO
9562
Non-Commercial
Interventional
No
48
COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial
13400
Non-Commercial
Interventional
No
9
De-ESCALaTE HPV
11723
Non-Commercial
Interventional
Yes
70
HOPON
4550
Non-Commercial
Interventional
Yes
21
IoN
10876
Non-Commercial
Interventional
Yes
17
NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC
11522
Commercial
Interventional
No
6
NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)
16203
Non-Commercial
Interventional
No
4
Slide20Head & Neck Tumour Group South West Peninsula Sites
Data from Portfolio ODP – Cut off 21/08/15
Slide21Head & Neck Tumour Group South West Peninsula Sites
Data from Portfolio ODP – Cut off 21/08/15
Trust
2014/2015
2015/2016
Commercial
Non-Commercial
Total
Commercial
Non-Commercial
Total
Northern Devon Healthcare NHS Trust
0
4
4
0
0
0
Plymouth Hospitals NHS Trust
0
15
15
0
0
0
Royal Cornwall Hospitals NHS Trust
0
0
0
0
0
0
Royal Devon and Exeter NHS Foundation Trust
1
18
19
0
0
0
South Devon Healthcare NHS Foundation Trust
0
12
12
0
0
0
Taunton and Somerset NHS Foundation Trust
0
8
8
0
0
0
Yeovil District Hospital NHS Foundation Trust
0
0
0
0
0
0
Slide22Head & Neck Tumour Group South West Peninsula
Open Studies 1Data from CRN SWP Activity Data from EDGE July 2015
Acronym
UKCRN ID
Study Type
Trust
Investigator Name
End Date
Target
Total Recruitment
2015/2016 Recruitment
RTT
ART-DECO
9562
Non-Commercial
Plymouth Hospitals NHS Trust
Roy, Dr Amy
31-Dec-20
8
4
0
19
ART-DECO
9562
Non-Commercial
Royal Devon and Exeter NHS Foundation Trust
Hwang, Dr David
26-Feb-16
12
5
0
-43
ART-DECO
9562
Non-Commercial
Taunton and Somerset NHS Foundation Trust
Jankowska, Dr Petra
29-Feb-16
2
0
0
-34
De-ESCALaTE HPV
11723
Non-Commercial
Royal Devon and Exeter NHS Foundation Trust
Hwang, Dr David
28-Feb-17
5
2
0
-9
HeadandNeck5000
9894
Non-Commercial
Northern Devon Healthcare NHS Trust
Hwang, Dr David
31-Dec-14
5
5
0
-52
HeadandNeck5000
9894
Non-Commercial
Taunton and Somerset NHS Foundation Trust
Jankowska
, Dr Petra
31-Dec-14
36
31
0
-37
HOPON
4550
Non-Commercial
Northern Devon Healthcare NHS Trust
Bowden, Dr John
28-Feb-18
3
0
0
-64
HOPON
4550
Non-Commercial
Taunton and Somerset NHS Foundation Trust
Blanco-Guzman, Manuel
28-Feb-18
2
0
0
-73
IoN
10876
Non-Commercial
Royal Devon and Exeter NHS Foundation Trust
Goodman, Dr Andrew
16-May-16
4
13
0
247
NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC
11522
Commercial
Royal Devon and Exeter NHS Foundation Trust
Hwang, Dr David
31-May-17
5
1
0
-41
Slide23Division 1
Duncan Wheatley, Clinical Specialty Lead
duncan.wheatley@rcht.cornwall.nhs.uk
01872 258312
Subspecialty
lead David Hwang
david.hwang@nhs.net
01392
406203
Wendy Cook, Research Delivery Manager
wcook1@nhs.net
01392 406995
Ann Courtman, Administrator
ann.courtman@nhs.net
01392 406966
23